Introduction {#j_tnsci-2018-0008_s_001}
============

In healthy populations, traumatic brain injury (TBI) has the highest mortality and is the costliest health problem worldwide \[[@j_tnsci-2018-0008_ref_001]\]. TBI can be subdivided into primary and secondary injury. Traumatic events cause the primary injury, while delayed processes associated with trauma lead to secondary injuries, such as the efflux of excitatory neurotransmitters, leading to oxidative stress, proteolysis, ATP depletion, ionic imbalance, and excitotoxicity \[[@j_tnsci-2018-0008_ref_002], [@j_tnsci-2018-0008_ref_003]\].

Several factors contribute to the development of secondary injury following TBI. For example, oxidative stress alters the balance between oxidants and antioxidants present in living cells \[[@j_tnsci-2018-0008_ref_004]\]. The presence of large amounts of polyunsaturated fatty acid in brain cells makes them more sensitive to oxidative stress-mediated neuronal damage \[[@j_tnsci-2018-0008_ref_005]\], resulting in increased damage to nucleic acids, proteins, and lipids \[[@j_tnsci-2018-0008_ref_006], [@j_tnsci-2018-0008_ref_007]\]. Endogenous antioxidants can protect against the oxidative stress-induced brain damage either by inhibiting the formation of reactive oxygen species (ROS) or by scavenging ROS \[[@j_tnsci-2018-0008_ref_008]\]. The secondary injury in TBI is due to ischemia, which results from the decreased blood flow after trauma. Moreover, ischemia results in Na/K/ATPase pump failure, since it is sensitive to oxidative stress \[[@j_tnsci-2018-0008_ref_009], [@j_tnsci-2018-0008_ref_010]\]. The blood--brain barrier (BBB) breaks down when the activity of the Na/K/ATPase pump is altered \[[@j_tnsci-2018-0008_ref_011]\]. Factors such as oxidative stress, myeloperoxidase activity, altered BBB permeability, and cerebral edema play roles in the development of secondary injury following TBI.

However, the secondary injury induced by TBI cannot be managed with existing drugs. Epifriedelinol (EFD), isolated from the roots of *Aster tataricus* \[[@j_tnsci-2018-0008_ref_012]\], has strong anti-inflammatory, antibacterial, antioxidant, and anti-cancer effects \[[@j_tnsci-2018-0008_ref_013], [@j_tnsci-2018-0008_ref_014]\]. This study evaluated the protective effects of EFD in TBI.

Material and methods {#j_tnsci-2018-0008_s_002}
====================

Animals {#j_tnsci-2018-0008_s_002_s_001}
-------

Albino Wistar rats were acclimatized in the animal facilities for 1 week before the experiment. The animals were housed under controlled conditions as specified in the animal care guidelines. All experimental procedures were approved by the ethics committee of Lanzhou University Second Hospital (IAEC/LUSH/2017/02).

Experiments {#j_tnsci-2018-0008_s_002_s_002}
-----------

The rats were divided randomly into four groups. The control group was given vehicle only. The TBI and EFD 100 and 200 groups were subjected to TBI. The EFD groups were given 100 and 200 mg/kg EFD, i.p. for 2 days beginning 30 min after induction of the brain trauma.

All animals were anesthetized with chlorpromazine (1 mg/kg) and ketamine (100 mg/kg) and a midline incision was made after shaving the scalp. Bone wax was used to fix a metallic disc in a central position. The rats were placed on a foam rubber platform and mild trauma was induced by dropping a 300-g steel weight from a height of 1 meter. At the end of the experiment, a neurological examination was performed and hematological and pathological changes were assessed in all animals.

Neurological examination {#j_tnsci-2018-0008_s_002_s_003}
------------------------

Behavioral and motor changes were assessed using the 20-point neuro score. The behavior assessments included the response to and circling of nociceptive stimuli, postural and walking reflexes, extremity tonus, performance in a smooth climbing platform, and consciousness.

Assessing the BBB permeability {#j_tnsci-2018-0008_s_002_s_004}
------------------------------

The integrity of the BBB was evaluated using the Evans Blue (EB) assay. At the end of the experiment, rats were anesthetized with chlorpromazine (1 mg/kg) and ketamine (100 mg/kg) and EB was injected through the jugular vein. The dye was allowed to circulate for 30 min. Then, saline solution was administered at a pressure of 110 mm Hg for 10 min for transcardial perfusion after opening the chest. The animals were sacrificed by decapitation and the cerebral cortex was isolated from the separated brain. EB-albumin extravasation was quantified in each cortex and protein precipitation was assessed after homogenizing the brain samples for 2 min with 2.5 mL of phosphate-buffered saline (PBS) and 2.5 mL of 60% trichloroacetic acid. The samples were centrifuged at 1000 rpm for 30 min after cooling. The absorbance of EB was determined at 620 nm using a spectrophotometer.

Assessing the brain water content {#j_tnsci-2018-0008_s_002_s_005}
---------------------------------

The brain was weighed, dried at 100°C for 2 days, and reweighed. The brain water content was estimated using the following formula:
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Measuring cytokine levels {#j_tnsci-2018-0008_s_002_s_006}
-------------------------

The plasma interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) concentrations were measured using enzyme-linked immunosorbent assays, as per the manufacturer's instructions.

Measuring oxidative stress markers {#j_tnsci-2018-0008_s_002_s_007}
----------------------------------

The serum malondialdehyde (MDA) level and superoxide dismutase (SOD) activity were determined using reported methods.

Estimating GFAP using immunohistochemistry {#j_tnsci-2018-0008_s_002_s_008}
------------------------------------------

The animals were anesthetized with an intraperitoneal injection of xylazine (10 mg/kg) and ketamine (75 mg/kg). Then, 200 mL of saline was injected into the left ventricle, followed by an equal volume of PBS. The brain tissue was fixed in PBS containing 15--30% sucrose at 4°C. Tissue sections were incubated for 48 h at 4°C with a polyclonal anti-rabbit glial fibrillary acidic protein (GFAP) antibody (1:3000). The samples were washed with PBS after incubation and incubated again at room temperature for 1 h with an anti-rabbit Alexa488 secondary antibody. Finally, the samples were washed several times with PBS and observed using an Olympus IX-81 confocal microscope.

Results {#j_tnsci-2018-0008_s_003}
=======

Effect of EFD on the neurological findings {#j_tnsci-2018-0008_s_003_s_001}
------------------------------------------

[Figure 1](#j_tnsci-2018-0008_fig_001){ref-type="fig"} shows the effects of EFD on the neuro score in the rat TBI model. The neuro score was significantly (*p* \< 0.01) higher in the TBI group compared with the controls. However, treatment with EFD significantly (*p* \< 0.01) decreased the neuro score in the TBI rats in a dose-dependent manner.

![The effects of epifriedelinol (EFD) on the neuro score in the rat traumatic brain injury (TBI) model. Mean ± standard deviation (SD) (n = 10), ^\*\*^*p* \< 0.01 compared with the controls; ^\#\#^*p* \< 0.01 compared with the TBI group.](tnsci-09-038-g001){#j_tnsci-2018-0008_fig_001}

Effect of EFD on the permeability of the BBB {#j_tnsci-2018-0008_s_003_s_002}
--------------------------------------------

[Figure 2](#j_tnsci-2018-0008_fig_002){ref-type="fig"} shows the effects of EFD on the BBB permeability and water content of the brain in the rat TBI model. The EB content and percentage water content in the brain were significantly higher in the TBI group than in the controls. There was a significant decrease in the BBB permeability and water content of the brain in the EFD-treated groups.

![The effects of EFD on the blood--brain barrier (BBB) permeability and water content of the brain in the rat TBI model. Mean ± SD (n = 10), ^\*\*^*p* \< 0.01 compared withthe controls; ^\#^*p* \< 0.05^\#\#^*p* \< 0.01 compared with the TBI group.](tnsci-09-038-g002){#j_tnsci-2018-0008_fig_002}

Effect of EFD on inflammatory cytokines {#j_tnsci-2018-0008_s_003_s_003}
---------------------------------------

[Figure 3](#j_tnsci-2018-0008_fig_003){ref-type="fig"} shows the effects of EFD on the serum cytokine levels in the rat TBI model. The TNF-α and IL-1β levels were significantly higher (*p* \< 0.01) in the TBI group compared with the controls, while they were significantly lower in the EFD-treated groups compared with the TBI group in a dose-dependent manner.

![The effects of EFD on serum tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) levels in the rat TBI model. Mean ± SD (n = 10), ^\*\*^*p* \< 0.01 compared with the controls; ^\#\#^*p* \< 0.01 compared with the TBI group.](tnsci-09-038-g003){#j_tnsci-2018-0008_fig_003}

Effects of EFD on oxidative stress {#j_tnsci-2018-0008_s_003_s_004}
----------------------------------

Evaluating parameters of oxidative stress, the MDA level increased significantly, while SOD activity decreased in the serum of the TBI group compared with the control rats. The EFD treatment significantly decreased the MDA level and increased the SOD activity in the serum of the TBI groups, as shown in [Figure 4](#j_tnsci-2018-0008_fig_004){ref-type="fig"}.

![The effects of EFD on oxidative stress parameters in the serum of TBI model rats. Mean ± SD (n = 10), ^\*\*^*p* \< 0.01 compared with Control; ^\#\#^*p* \< 0.01 compared with TBI.](tnsci-09-038-g004){#j_tnsci-2018-0008_fig_004}

Effect of EFD on GFAP-positive cells {#j_tnsci-2018-0008_s_003_s_005}
------------------------------------

[Figure 5](#j_tnsci-2018-0008_fig_005){ref-type="fig"} shows the effects of EFD on GFAP-positive cells in the hippocampus of the TBI model rats. The number of GFAP-positive cells was significantly higher in the hippocampus of the TBI group rats compared with the controls. There was a significant decrease in GFAP-positive cells in the hippocampus of the EFD-treated groups compared with the TBI group.

![The effects of EFD on GFAP-positive cells in the hippocampus of the TBI model rats. Mean ± SD (n = 10), ^\*\*^*p* \< 0.01 compared with the controls; ^\#\#^*p* \< 0.01 compared with the TBI group.](tnsci-09-038-g005){#j_tnsci-2018-0008_fig_005}

Discussion {#j_tnsci-2018-0008_s_006}
==========

The mechanism of secondary injury in TBI at the molecular level is not completely understood. Therefore, this study examined the molecular pathology of TBI and evaluated the protective effects of EFD. Following trauma, many pathological changes lead to brain edema, decreased blood flow, and ischemia \[[@j_tnsci-2018-0008_ref_015]\]. Processes responsible for the increase in secondary brain injury include chemokine generation, cytokines, the production of adhesion molecules, inflammation, and the generation of free radicals \[[@j_tnsci-2018-0008_ref_016]\]. In TBI, the increased cytokine levels cause BBB dysfunction, cell death, and cerebral damage \[[@j_tnsci-2018-0008_ref_017]\]. The neuroinflammation in TBI is promoted by IL-1, which stimulates proinflammatory factors like TNF-α \[[@j_tnsci-2018-0008_ref_018], [@j_tnsci-2018-0008_ref_019]\]. Hyperinflammation develops because of the presence of proinflammatory mediators in circulation. Our data revealed that treatment with EFD decreased the level of inflammatory mediators in the blood of TBI rats compared with the control group. Moreover, it maintained the integrity of the BBB and water content in the brains of the TBI rats.

Oxidative stress contributes to the development of secondary injury in TBI and antioxidants have a protective effect \[[@j_tnsci-2018-0008_ref_020]\]. Our results suggest that treatment with EFD attenuates oxidative stress in the serum in TBI and decreases the number of GFAP-positive cells in the brain.

Conclusions {#j_tnsci-2018-0008_s_007}
-----------

EFD attenuates the secondary injury in TBI in rats by ameliorating the altered serum cytokine levels and oxidative stress.
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